

NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Follicular Lymphoma (Grade 1, 2) (Part 1 of 3)

The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. The cancer treatment regimens below may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient.

REGIMEN	DOSING
First-line Therapy	
Bendamustine (Treanda) + rituximab (Rituxan) ^{1,2}	Day 1: Rituximab 375mg/m ² IV. Days 1 and 2: Bendamustine 90mg/m ² IV. Repeat cycle every 4 weeks for a max of 6 cycles.
R-CHOP (rituximab + cyclophosphamide [Cytosan] + doxorubicin [Adriamycin] + vincristine [Oncovin] + prednisone) ^{1,3,4} NOTE: Category 1	Day 1: Rituximab 375mg/m ² IV (day before CHOP). Day 1: Cyclophosphamide 750mg/m ² IV + doxorubicin 50mg/m ² IV + vincristine 1.4mg/m ² IV (max dose 2mg). Days 1-5: Prednisone 100mg/m ² orally once daily. Repeat cycle every 3 weeks for 6-8 cycles.
RCVP (rituximab + cyclophosphamide + vincristine + prednisone) ^{1,5} NOTE: Category 1	Day 1: Rituximab 375mg/m ² IV. Day 1: Cyclophosphamide 750mg/m ² IV + vincristine 1.4mg/m ² IV (max dose 2mg). Days 1-5: Prednisone 40mg/m ² orally once daily.
Fludarabine (Fludara) + rituximab ^{1,6}	Weeks 1 and 26 Days 1 and 5: Rituximab 375mg/m ² IV. Cycles 2, 4, and 6 Day 1: Rituximab 375mg/m ² IV 72 hrs prior to fludarabine. Week 2 of each cycle Days 1-5: Fludarabine 25mg/m ² IV. Repeat cycle every 4 weeks for 6 cycles.
RFND (rituximab + fludarabine + mitoxantrone [Novantrone] + dexamethasone) ^{1,6}	Days 1-3: Fludarabine 25mg/m ² IV. For Cycles 2-5 , fludarabine is given on Days 2-4 . Day 1: Mitoxantrone 10mg/m ² IV. For Cycles 2-5 , mitoxantrone is given on Day 2 . Days 1-5: Dexamethasone 20mg/m ² IV or orally. Days 1 and 8 for Cycle 1: Rituximab 375mg/m ² IV. Day 1 for Cycles 2-5: Rituximab 375mg/m ² IV. Repeat cycle every 4 weeks.
Rituximab ^{1,7,8}	Day 1: Rituximab 375mg/m ² IV once a week for 4 weeks.
First-line Therapy for Elderly or Infirm (if none of the above is tolerable)	
Tositumomab and Iodine I-131 tositumomab (Bexxar) ^{1,9-11}	Step 1 (Dosimetric step). Day 1: Tositumomab 450mg IV, followed by I-131 tositumomab (35mg) IV. Day 2, 3, or 4: Second scan. Day 6 or 7: Third scan. Step 2 (Therapeutic step). Give 7-14 days after Step 1. Day 1: Tositumomab 450mg IV, followed by I-131 tositumomab (35mg) IV labeled with an amount (in millicuries) of iodine-131 calculated from serial total-body gamma-camera counts after the dosimetric dose to deliver a dose of total-body radiation of 75 cGy.
Rituximab (preferred) ^{1,7,8}	Day 1: Rituximab 375mg/m ² IV once a week for 4 weeks.
Cyclophosphamide ± rituximab ^{1,7,8,12}	Cyclophosphamide 100mg/m ² orally every day until complete response. Can be continued up to 2 years. Day 1: Rituximab 375mg/m ² IV once a week for 4 weeks.

continued

NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Follicular Lymphoma (Grade 1, 2) (Part 2 of 3)

REGIMEN	DOSING
First-line Consolidation or Extended Dosing (optional)	
Chemotherapy followed by radioimmunotherapy (Category 1)	
CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone), followed by tositumomab and iodine I-131 tositumomab therapy ^{1,9-11,13,14}	CHOP Day 1: Cyclophosphamide 750mg/m ² IV + doxorubicin 50mg/m ² IV + vincristine 1.4mg/m ² IV (max dose 2mg). Days 1-5: Prednisone 100mg/day orally. Repeat cycle every 3 weeks for 6 cycles. <u>Tositumomab and iodine I-131 tositumomab</u> Step 1 (Dosimetric step) Day 1: Tositumomab 450mg IV, followed by I-131 tositumomab (35mg) IV. Day 2, 3, or 4: Second scan. Day 6 or 7: Third scan. Step 2 (Therapeutic step) Give 7-14 days after Step 1. Day 1: Tositumomab 450 mg IV, followed by I-131 tositumomab (35 mg) IV, labeled with an amount (in millicuries) of iodine-131 calculated from serial total-body gamma-camera counts after the dosimetric dose to deliver a dose of total-body radiation of 75 cGy.
Chemotherapy followed by consolidation therapy	
Bendamustine + rituximab ^{1,2}	Day 1: Rituximab 375mg/m ² IV. Days 1 and 2: Bendamustine 90mg/m ² IV. Repeat cycle every 4 weeks for a max of 6 cycles.
R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) ^{1,3,4} NOTE: Category 1	Day 1: Rituximab 375mg/m ² IV (day before CHOP). Day 1: Cyclophosphamide 750mg/m ² IV + doxorubicin 50mg/m ² IV + vincristine 1.4mg/m ² IV (max dose 2mg). Days 1-5: Prednisone 100mg/m ² orally once daily. Repeat cycle every 3 weeks for 6-8 cycles.
RCVP (rituximab + cyclophosphamide + vincristine + prednisone) ^{1,5} NOTE: Category 1	Day 1: Rituximab 375mg/m ² IV. Day 1: Cyclophosphamide 750mg/m ² IV + vincristine 1.4mg/m ² IV (max dose 2mg). Days 1-5: Prednisone 40mg/m ² orally once daily.
Fludarabine + rituximab ^{1,6}	<u>Weeks 1 and 26</u> Days 1 and 5: Rituximab 375mg/m ² IV. <u>Cycles 2, 4, and 6</u> Day 1: Rituximab 375mg/m ² IV 72 hrs prior to fludarabine. <u>Week 2 of each cycle</u> Days 1-5: Fludarabine 25mg/m ² IV. Repeat cycle every 4 weeks for 6 cycles.
RFND (rituximab + fludarabine + mitoxantrone + dexamethasone) ^{1,6} Followed by consolidation therapy	Days 1-3: Fludarabine 25mg/m ² IV. For Cycles 2-5 , fludarabine is given on Days 2-4 . Day 1: Mitoxantrone 10mg/m ² IV. For Cycles 2-5 , mitoxantrone is given on Day 2 . Days 1-5: Dexamethasone 20mg/m ² IV or orally. Days 1 and 8 for Cycle 1: Rituximab 375mg/m ² IV. Day 1 for Cycles 2-5: Rituximab 375mg/m ² IV. Repeat cycle every 4 weeks.
Rituximab + ⁹⁰Y-ibritumomab tiuxetan (Zevalin) ^{1,15,16}	Days 1 and 7: Rituximab 250mg/m ² IV. Day 7: ⁹⁰ Y-ibritumomab tiuxetan 14.8MBq/kg (not to exceed 1,184MBq) immediately after rituximab.
Chemotherapy plus rituximab followed by rituximab maintenance up to 2 years (Category 1)	
RCVP (cyclophosphamide + vincristine + prednisone) ^{1,12}	Day 1: Rituximab 375mg/m ² IV. Day 1: Cyclophosphamide 750mg/m ² IV + vincristine 1.4mg/m ² IV (max dose 2mg). Days 1-5: Prednisone 40mg/m ² orally once daily. Repeat cycle every 3 weeks for 8 cycles.

continued

NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Follicular Lymphoma (Grade 1, 2) (Part 3 of 3)

REGIMEN	DOSING
Chemotherapy plus rituximab followed by rituximab maintenance up to 2 years (Category 1) (continued)	
R-CHOP (cyclophosphamide + doxorubicin + vincristine + prednisone) ^{1,12}	<p>Day 1: Rituximab 375mg/m² IV, followed by rituximab 375mg/m² IV for 2 additional doses every 3 weeks after the last cycle.</p> <p>Day 1: Cyclophosphamide 750mg/m² IV + doxorubicin 50mg/m² IV + vincristine 1.4mg/m² IV (max dose 2mg).</p> <p>Days 1-5: Prednisone 100mg/m² orally once daily.</p> <p>Repeat cycle every 3 weeks for 6 cycles.</p>
FCM (fludarabine + cyclophosphamide + mitoxantrone) + rituximab ^{1,12}	<p>Days 1-3: Fludarabine 25mg/m² IV.</p> <p>Days 1-3: Cyclophosphamide 200mg/m² orally.</p> <p>Day 1: Mitoxantrone 6mg/m² IV.</p> <p>Day 1: Rituximab 375mg/m² IV, followed by rituximab 375mg/m² IV for 2 additional doses given 2 weeks after Cycles 1 and 4.</p> <p>Repeat cycle every 4 weeks for 6 cycles.</p>
<u>Followed by rituximab maintenance therapy</u>	
For patients with complete or partial response to chemotherapy and received 6 cycles of RCVP, 4 cycles R-CHOP, or 4 cycles R-FCM ^{1,12}	Day 1: Rituximab 375mg/m ² IV for 12 infusions every 8 weeks, starting 8 weeks after last induction treatment.

References

- NCCN Clinical Practice Guidelines in Oncology™. Non-Hodgkin's Lymphomas. v 3.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed July 7, 2012.
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression-free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. *Blood*. 2009;114:Abstract 405.
- Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood*. 2005;106:3725-3732.
- Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. *J Clin Oncol*. 2004;22:4711-4716.
- Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. *Blood*. 2005;105:1417-1423.
- McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. *Semin Oncol*. 2000;27(supple 12):37-41.
- Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. *J Clin Oncol*. 2002;20:4261-4267.
- Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. *Blood*. 2001;97:101-106.
- Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. *N Engl J Med*. 2005;352:441-449.
- Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. *Blood*. 2009;114:Abstract 3759.
- Bexar [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
- Peterson BA, Petroni GR, Frizzera G, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. *J Clin Oncol*. 2003;21:5-15.
- Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet*. 2011;377: 42-51.
- Press OW, Unger JM, Brazier RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. *J Clin Oncol*. 2006;24:4143-4149.
- Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *J Clin Oncol*. 2008;26:5156-5164.
- Zevalin [package insert]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; 2002.